Murdoch University Research Repository

Welcome to the Murdoch University Research Repository

The Murdoch University Research Repository is an open access digital collection of research
created by Murdoch University staff, researchers and postgraduate students.

Learn more

The dynamics of HCV-specific antibody responses in HIV/HCV patients on long-term antiretroviral therapy

Lee, S., Laiman, A., French, M.A, Flexman, J., Watson, M.W.ORCID: 0000-0002-6438-9225 and Price, P. (2017) The dynamics of HCV-specific antibody responses in HIV/HCV patients on long-term antiretroviral therapy. Clinical Immunology, 179 . pp. 54-63.

PDF - Authors' Version
Download (1MB) | Preview
Link to Published Version:
*Subscription may be required


Antibody responses have not been fully characterised in chronically HIV/HCV patients receiving antiretroviral therapy (ART). Seventeen HIV/HCV patients receiving ART were followed for a median (range) interval of 597 (186–766) weeks. Prior to ART, HIV/HCV patients had lower levels of antibodies reactive with HCV core and JFH-1, and lower genotype cross-reactive neutralising antibodies (nAb) titres, than HCV patients. Levels of JFH-1 reactive antibody increased on ART, irrespective of CD4+ T-cell counts or changes in serum ALT levels. The appearance of nAb coincided with control of HCV viral replication in five HIV/HCV patients. In other patients, HCV viral loads remained elevated despite nAb responses. Sustained virological responses following HCV therapy were associated with reduced antibody responses to JFH-1 and core but elevated responses to non-structural proteins. We conclude that nAb responses alone may fail to clear HCV, but contribute to control of viral replication in some HIV/HCV patients responding to ART.

Item Type: Journal Article
Murdoch Affiliation(s): Centre for Clinical Immunology and Biomedical Statistics
Publisher: Academic Press Inc.
Copyright: © 2017 Elsevier Inc.
Item Control Page Item Control Page


Downloads per month over past year